Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | LAP3 | P28838 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80417 | 0.82 | SRC (0.52) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL2303782 | 0.82 | SRC (0.52) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL27836558 | 0.82 | SRC (0.52) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL25883278 | 0.79 | SRC (0.48) | SRCL3MBTL1TDP1ANPEPLAP3 | |
| SCHEMBL9911203 | 0.79 | SRC (0.48) | SRCL3MBTL1TDP1ANPEPLAP3 | |
| SCHEMBL27881894 | 0.78 | SRC (0.47) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL17305220 | 0.78 | L3MBTL1 (0.50) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL2497223 | 0.78 | L3MBTL1 (0.50) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| SCHEMBL734215 | 0.78 | SRC (0.61) | SRCL3MBTL1TDP1CYP2C9CYP2C19 | |
| Phosphoric Acid SCHEMBL29974301 | 0.78 | SRC (0.47) | SRCL3MBTL1TDP1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834224-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LAB LTD (IN) | 2018-06-06 | — | — | EP | claimed |
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | claimed |
| EP-2834224-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN Laboratories Limited (IN) | 2015-02-11 | — | — | EP | claimed |
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | claimed |
| WO-2013150545-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LABORATORIES LIMITED (IN) | 2013-10-10 | — | — | WO | claimed |
| WO-2011138795-A2 | PROCESS FOR PREPARING (S)-10-ACETOXY-10,11-DIHYDRO-5H-DIBENZ[B,F] AZEPINE-5-CARBOXAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-11-10 | — | — | WO | claimed |
| EP-0565567-B1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | LEPETIT SPA (IT) | 1995-01-18 | — | — | EP | claimed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-2834224-B1 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN LAB LTD (IN) | 2018-06-06 | — | — | EP | disclosed |
| EP-2294053-B1 | GLUCOKINASE ACTIVATORS | TAKEDA CALIFORNIA INC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2834224-A2 | PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES AND SALTS THEREOF | MSN Laboratories Limited (IN) | 2015-02-11 | — | — | EP | disclosed |
| WO-2014061034-A1 | PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-04-24 | — | — | WO | disclosed |
| EP-2654751-A1 | PHOSPHORUS-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | Purdue Pharma L.P. (US) | 2013-10-30 | — | — | EP | disclosed |
| CN-1149085-C | Inhibition of RAF kinase with substituted heterocyclic ureas | — | 2004-05-12 | — | — | CN | disclosed |
| CN-1119343-C | Substituted aminocycloalkylpyrrolidine derivatives | DAIICHI SEIYAKU CO (JP) | 2003-08-27 | — | — | CN | disclosed |
| CN-1341098-A | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER AG (US) | 2002-03-20 | — | — | CN | disclosed |
| CN-1064044-C | Heterocyclic compounds, their productin and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-04 | — | — | CN | disclosed |
| CN-1040755-C | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-11-18 | — | — | CN | disclosed |
| CN-1079966-A | Heterogeneous ring compound, its preparation and application | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-12-29 | — | — | CN | disclosed |
| CN-1067890-A | Heterogeneous ring compound, its preparation and application | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087842-A1 | Process For The Preparation Of Benzimidazole Derivatives And Salts Thereof | AZI2, IL4I1, ABAT | SRC 1746/4885L3MBTL1 3779/4885TDP1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.